TL;DR: A 2026 Neurological Sciences study followed 216 early Parkinson’s patients for 2 years after levodopa started and found that several non-motor symptom differences between men and women persisted or emerged despite adjustment for baseline scores and levodopa dose. Key Findings 216 early Parkinson’s patients completed 24-month follow-up after starting levodopa, including 139 men and …
TL;DR: A 2026 medRxiv preprint linked pre-surgery diffusion MRI markers in Parkinson’s disease to 6-month changes in impulsive-compulsive behaviour after subthalamic deep brain stimulation. Key Findings Small DBS cohort: Researchers followed 35 Parkinson’s disease patients from preoperative diffusion MRI to 6-month clinical follow-up after subthalamic deep brain stimulation. Behaviour score: Impulsive-compulsive behaviour was measured with …
TL;DR: A 2026 medRxiv preprint found psychomotor retardation, meaning slowed movement, speech, and thinking during depression, was linked to higher later Parkinson’s diagnosis risk in 6,327 London mental-health records. Key Findings Psychomotor retardation was common: Among 6,327 people with depression at age 40 or older, 2,402 patients, or 38.0%, had psychomotor retardation documented in records. …
TL;DR: A 2026 study in Molecular Neurobiology found that Antrodia cinnamomea, a medicinal fungus extract, worked best when carried on citrate-stabilized silver nanoparticles in cell and rat models of Parkinson’s-like dopamine injury. Key Findings 6-OHDA created Parkinson’s-like injury: The toxin reduced SH-SY5Y cell viability and produced unilateral dopamine-system damage in rats. Combination treatment was strongest: …
TL;DR: A 2026 npj Parkinson’s Disease study used brain transcriptome data and genome-scale metabolic modeling to predict Parkinson’s metabolite biomarkers, including dopamine-related changes, and separated 104 postmortem samples into three metabolic clusters. Key Findings Metabolic model: The study used TAMBOOR, a transcriptome-based metabolic modeling algorithm, to predict metabolite oversecretion and undersecretion. Brain tissue data: The …
TL;DR: A 2026 preprint on medRxiv using the Harvard Biomarkers Study found that 43% of Parkinson’s disease patients had depression, anxiety, sleep apnea, or restless legs syndrome, compared with 21% of controls. Key Findings 1,224-person cohort: Researchers analyzed 933 Parkinson’s disease cases and 291 controls in the Harvard Biomarkers Study. 43% mood-sleep burden: At least …
TL;DR: A 2026 systematic review and exploratory network meta-analysis of 5 randomized trials in Neurological Sciences found dose-specific ON-medication motor improvements, measured while usual Parkinson’s drugs were active, for some GLP-1 receptor agonists, glucose-related metabolic hormone drugs, in Parkinson’s disease, but broader motor, non-motor, and quality-of-life evidence remained limited. Key Findings 5 randomized trials: The …
TL;DR: A 2026 medRxiv preprint found that targeted memory reactivation (TMR), replaying learned sounds during non-REM sleep, changed spindle and slow-wave density during a nap but did not improve motor memory retention in Parkinson’s disease or healthy older adults. Key Findings Parkinson’s and healthy older adults were compared: The experiment included 20 people with Parkinson’s …
Gut Microbiome Signal Appeared Before Parkinson’s Symptoms in GBA1 Carriers TL;DR: In people carrying a genetic risk factor for Parkinson’s but not yet symptomatic, about 25% of their gut microbiome signature already looked intermediate between healthy controls and diagnosed patients — and the shift tracked with early warning signs like sleep disruption and smell loss. …
How the Brain Hijacks Balance Control in Parkinson’s TL;DR: When older adults face large balance challenges, their brains shift from relying on quick brainstem reflexes to slower cortical circuits—a shift that happens even in Parkinson’s disease, revealing a mechanistic window into age-related balance loss. Balance isn’t automatic. When you stumble forward or feel the ground …
